California First Leasing Corp’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-132,800
Closed -$8.1M 43
2025
Q1
$8.1M Hold
132,800
3.57% 7
2024
Q4
$7.51M Hold
132,800
3.1% 10
2024
Q3
$6.87M Hold
132,800
2.99% 11
2024
Q2
$5.52M Hold
132,800
2.47% 15
2024
Q1
$7.2M Hold
132,800
3.35% 11
2023
Q4
$6.81M Hold
132,800
3.62% 10
2023
Q3
$7.71M Hold
132,800
4.46% 5
2023
Q2
$8.49M Hold
132,800
5.19% 6
2023
Q1
$9.2M Hold
132,800
6.15% 4
2022
Q4
$9.55M Hold
132,800
6.64% 4
2022
Q3
$9.44M Hold
132,800
7.13% 3
2022
Q2
$10.2M Sell
132,800
-22,000
-14% -$1.68M 7.78% 3
2022
Q1
$11.3M Hold
154,800
6.28% 4
2021
Q4
$9.65M Buy
+154,800
New +$9.08M 4.79% 8

Other funds holding BMY

California First Leasing Corp's BMY Position: Q2 2025 in Review

California First Leasing Corp sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 132,800 shares — an estimated $8.1M sold.

California First Leasing Corp first reported a position in BMY in Q4 2021 and held it in 14 quarters. The position peaked at $11.3M in Q1 2022. 2,297 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

  • California First Leasing Corp reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
  • California First Leasing Corp sold 132,800 Bristol-Myers Squibb shares in Q2 2025, an estimated $8.1M.
  • California First Leasing Corp first reported a position in Bristol-Myers Squibb in Q4 2021 and held it in 14 quarters.
  • California First Leasing Corp's Bristol-Myers Squibb position peaked at $11.3M in Q1 2022.
  • 2,297 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on California First Leasing Corp's 13F filing for Q2 2025, filed 13 Aug 2025.